Compare MNSB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MNSB | ACOG |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 129.4M |
| IPO Year | N/A | N/A |
| Metric | MNSB | ACOG |
|---|---|---|
| Price | $20.53 | $5.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 33.3K | ★ 65.6K |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,367,000.00 | $7,427,199.00 |
| Revenue This Year | $21.22 | N/A |
| Revenue Next Year | $3.33 | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $15.00 | $3.75 |
| 52 Week High | $22.98 | $11.54 |
| Indicator | MNSB | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 46.67 |
| Support Level | $19.77 | $5.20 |
| Resistance Level | $21.45 | $6.04 |
| Average True Range (ATR) | 0.58 | 0.46 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 56.28 | 41.87 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.